Together, Little Place Labs and Loft Orbital are paving the way for a new era of rapid-response capabilities in space. Photo courtesy of Little Place Labs

A Houston space startup has announced a new partnership that will “push the boundaries of real-time data processing and insight delivery.”

Little Place Labs is collaborating with San Francisco-based Loft Orbital to pair its low-latency operations, using its space infrastructure with LittlePlace Labs’ cutting-edge analytics. This will enhance maritime domain awareness under a US Air Force Phase 2 STTR by deploying Little Place Labs software to Loft’s YAM-6 satellite as a virtual mission.

“Our on-orbit data processing solutions, paired with Loft’s satellite platform, allow us to derive and deliver insights in near real-time for time-sensitive situations,” Little Place Labs Co-founder and CEO Bosco Lai says in a news release. “These insights are critical to commercial and national security stakeholders, including those in the US government. This collaboration highlights the new space age, where companies like Little Place Labs and Loft come together, integrating our solutions into powerful capabilities.”

Loft plans to deploy Little Place Labs’ applications to its constellation of satellites. Each satellite node will be equipped with a sensing resource like visible and infrared images, and configurable software-defined radios. The satellite nodes make up Loft’s space infrastructure, which will include onboard edge compute and connectivity resources. The infrastructure will be used to build and complete complex missions. The low-latency maritime domain awareness is an example of the complex challenges that won’t involve deployment of new hardware. This aligns with both companies goals to address real-time data solutions and rapid responses in space.

"We are proud to support customers like Little Place Labs in pushing the limits of what’s possible with low latency applications and onboard edge compute,” Mitchell Scher, director of business development at Loft, adds. “While we’re providing the infrastructure to support these kinds of low-latency operations, it is only as useful as the applications our customers deploy and the operational value they produce for their end users.”

Little Place Labs will be working with another military organization, as they were recently selected by AFWERX for a STTR Phase II contract in the amount of $1.8 million dollars. The focus will be “revolutionizing space- based ISR through decentralized systems,” per a news release. This will be done in-orbit ML computing for near-real-time intelligence to address challenges in the Department of the Air Force.

Another recent collaboration sees their Orbitfy software suite on LEOcloud’s Space Edge infrastructure as a Service (IaaS). This will help facilitate “scalable real-time data processing and analysis directly on spacecraft, significantly reducing downlink costs and enabling faster mission-critical insight,” according to a news release. The Orbitfy Software suite combines data preprocessing capabilities with low-SWaP machine learning applications that is designed for deployment directly on space infrastructures and satellites.

Little Place Labs is also using its satellite real-time solutions to help address wildfires. They were one of four companies part of the completion of the first round of the XPRIZE Autonomous Wildfire Challenge by the coalition Fire Foresight.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”